Last Updated: 06/06/2026

Freenome

Nottingham

Founded 2002

Multiomics blood-based platform for early-stage cancer detection

Freenome is a biotechnology company developing blood-based early cancer detection tests using a multiomics platform that combines tumour and non-tumour biological signals with machine learning.

The UK subsidiary, based in Nottingham, holds the autoantibody immunodiagnostic technology and cancer detection pipeline acquired from Oncimmune, including a commercialised CE-IVD marked blood test for lung cancer deployed within the NHS Lung Health Check Programme.

Biotech Diagnostics & Biomarkers Oncology AI & Machine Learning

Liquid Biopsy In Vitro Diagnostics Respiratory Disease

Is this your company?

Claim this page to receive a verified badge and keep your profile up to date.

Claim page